Videos

Nicole Petrykowski on Desmoid Tumor Treatment and Management

Nicole Petrykowski, DNP, FNP-C, OCN , focuses on desmoid tumor treatment and management, emphasizing shared decision-making with patients. Initial management often involves observation with scans every 3-6 months. Treatment, using sorafe...

January 27, 2025

Best Practices Summit Sarcoma

Alexis Spence on the Pharmacist Role in Desmoid Treatment

Alexis Spence, PharmD, BCOP, shares how clinic pharmacists play a vital role in the care of sarcoma patients, especially those with rare desmoid tumors. They provide an extra layer of support, reviewing medications for potential interact...

January 27, 2025

Best Practices Summit Sarcoma

Anne Mailhot on Desmoid Tumor Treatment Initiation, Duration, and Side Effects

Anne Mailhot, PA-C, discusses how her clinic focuses on managing symptoms, primarily pain and quality of life, rather than solely the size of the desmoid tumor. Treatment begins when symptoms interfere with daily life, and its duration i...

January 27, 2025

Best Practices Summit Sarcoma

Julie Messina on Desmoid Tumors and Fertility Preservation

Julie Messina, PA-C, explores desmoid tumors treatments and how they often use agents that can affect fertility. Treatment options include nirogacestat and sorafenib, but data on the effects of tyrosine kinase inhibitors on fertility is ...

January 27, 2025

AP Perspectives Symptom Management

GVHD Prophylaxis: Ruxolitinib and De-escalated PTCy for Older Patients

Katie Sellers, MPAS, PA-C, discusses a phase II trial presented at the ASH Annual Meeting exploring de-escalated post-transplant cyclophosphamide (PTCy) with ruxolitinib for GVHD prophylaxis in older patients undergoing reduced intensity...

December 26, 2024

AP Perspectives Symptom Management

PTCy is Standard of Care: Improved GVHD Control and Survival in Older Patients

Katie Sellers, MPAS, PA-C, considers a post-hoc analysis focusing on transplant recipients aged ≥70 years in the BMT CTN 1703 trial (Abstract 1042). The study found that even in this older, frailer sub-population, post-transplant cycloph...

December 26, 2024

AP Perspectives Symptom Management

Axatilimab for Chronic Graft-vs.-Host Disease

Katie Sellers, MPAS, PA-C, reviews findings from the Agave-201 study presented at the ASH Annual Meeting, which evaluated axatilimab, an anti-CSF1R monoclonal antibody, in chronic graft-versus-host disease (Abstract 98). Axatilimab showe...

December 23, 2024

Meeting Highlights Classical Hematology

Emicizumab Prophylaxis Instead of Immunosuppression During Early Management of Acquired Hemophilia A

Brad Lewis, MD, of Machaon Diagnostics, covers an analysis of data from 2 studies in patients with acquired hemophilia A. The objective of the current analysis was to report long-term outcomes of emicizumab prophylaxis compared with trad...

December 23, 2024

Meeting Highlights Classical Hematology

Silent Cerebral Infarction as a Potential Predictor of Stroke in Immune TTP Survivors

Brad Lewis, MD, of Machaon Diagnostics, highlights a study that built on data from the NeST (Neurologic Sequelae of TTP) study and evaluated whether silent cerebral infarction (SCI) is progressive during immune thrombotic thrombocytopeni...

December 23, 2024

Meeting Highlights Classical Hematology

Assessing the Safety and Efficacy of the Novel Allosteric AKT Inhibitor VAD044 in Hereditary Hemorrhagic Telangiectasia

Brad Lewis, MD, of Machaon Diagnostics, reports on a study that evaluated the safety and efficacy of two doses of VAD044 in adults with moderate to severe hereditary hemorrhagic telangiectasia. Results showed that safety and tolerability...

December 23, 2024

Meeting Highlights Myeloproliferative Neoplasms

Real-World Outcomes in Patients with Myelofibrosis Treated with Momelotinib in the Community Oncology Setting

Viviana Perez, APRN, FNP-C, of Moffitt Cancer Center, discusses the first real-world study (N = 4,019) of momelotinib use in patients with myelofibrosis and anemia in the US community oncology practice setting. The results provide import...

December 23, 2024

Meeting Highlights Lymphoma

A Healthcare Utilization Model Comparing Time Toxicity Between Glofitamab and Epcoritamab

Viviana Perez, APRN, FNP-C, of Moffitt Cancer Cancer, discusses research evaluating how differences in “time toxicity” of the bispecific antibodies (BsAbs) glofitamab and epcoritamab may help guide decision-making for patients with relap...

December 23, 2024

Meeting Highlights Lymphoma

Real-World Outcomes of CD19 CAR-T in Patients with R/R Transformed Indolent Lymphoma

Viviana Perez, APRN, FNP-C, of Moffitt Cancer Cancer, discusses a multicenter, retrospective study evaluating the safety and efficacy of standard-of-care CD19 CAR T-cell therapy in adults with relapsed/refractory transformed indolent NHL...

December 23, 2024

Meeting Highlights Lymphoma

Evaluating the Need for Autologous Transplant in Mantle Cell Lymphoma

Laura Zitella, MS, RN, ACNP-BC, AOCN, of UCSF, reviews data that challenge the role of autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL). The TRIANGLE trial demonstrated superior failure-free and overall survival ...

December 20, 2024

$CD19-Directed Monoclonal Antibodies in Relapsed/Refractory Follicular Lymphoma$

Meeting Highlights Lymphoma

CD19-Directed Monoclonal Antibodies in Relapsed/Refractory Follicular Lymphoma

Laura Zitella, MS, RN, ACNP-BC, AOCN, of USCF, discusses abstracts that highlight the potential role of CD19-directed monoclonal antibodies for relapsed/refractory follicular lymphoma. The first showed a decreased risk of progression, re...

December 20, 2024

Meeting Highlights Multiple Myeloma

Assessing When to Stop Lenalidomide Maintenance in Multiple Myeloma

Laura Zitella, MS, RN, ACNP-BC, AOCN, of UCSF, discusses a prospective study of patients with newly diagnosed MM who underwent autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance, to investigate the optimal d...

December 20, 2024

AP Perspectives Myeloproliferative Neoplasms

Burdens and QOL Impacts of Anemia and Transfusion Dependence in Myelofibrosis

Lindsey E. Kalhagen, MMS, PA-C, discusses a multinational, cross-sectional, online survey study (N = 155) that expanded on previous findings that 20 participants with myelofibrosis (MF) reported, in a series of elicitation interviews, su...

December 19, 2024

AP Perspectives Myeloproliferative Neoplasms

Combination Interferon and Ruxolitinib vs Ruxolitinib in Myelofibrosis

Lindsey E. Kalhagen, MMS, PA-C, discusses a single-center, retrospective, propensity-score matched study that compared clinical response, progression-free survival (PFS) and overall survival (OS) outcomes, and adverse events in 62 patien...

December 19, 2024

AP Perspectives Myeloproliferative Neoplasms

Real-World Outcomes of Momelotinib as a Therapy Option in Myelofibrosis Patients With Anemia

Lindsey E. Kalhagen, MMS, PA-C, discusses a multicenter, observational, retrospective study involving myelofibrosis patients with splenomegaly or symptoms and anemia who received momelotinib from March 2023 to July 2024. This study inclu...

December 19, 2024

Meeting Highlights

Gloria  Espinosa, PharmD, MAT, BCOP, on Safety of Quizartinib by Treatment Phase and Age in FLT3-ITD–Positive Acute Myeloid Leukemia

Gloria  Espinosa, PharmD, MAT, BCOP, of Thomas Jefferson University Hospital, comments on the safety data of the FLT3 inhibitor quizartinib in patients with FLT3-ITD–positive acute myeloid leukemia. Infections and cytopenias were observe...

$Gloria  Espinosa, PharmD, MAT, BCOP, on Efficacy and Safety of Revumenib in Patients With Relapsed/Refractory KMT2Ar Acute Leukemia$

Meeting Highlights

Gloria  Espinosa, PharmD, MAT, BCOP, on Efficacy and Safety of Revumenib in Patients With Relapsed/Refractory KMT2Ar Acute Leukemia

Gloria Espinosa, PharmD, MAT, BCOP, of Thomas Jefferson University Hospital, discusses efficacy and safety data for the first-in-class menin inhibitor, revumenib, in patients with relapsed/refractory KMT2A-rearranged acute leukemia. The ...

$Tiffany Richards, PhD, ANP-BC, AOCNP, on Responses to a GPRC5D-Targeted CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma$

Meeting Highlights

Tiffany Richards, PhD, ANP-BC, AOCNP, on Responses to a GPRC5D-Targeted CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, reviews updated efficacy and safety data for BMS-986393 (CC‑95266), a GPRC5D-targeted autologous chimeric antigen receptor (CAR) T-cell therapy ...

Meeting Highlights

Tiffany Richards, PhD, ANP-BC, AOCNP, on Newly Diagnosed Multiple Myeloma: Findings on DARA + VRd vs. VRd Alone

Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, examines daratumumab (DARA) plus bortezomib, lenalidomide, and dexamethasone (VRd) vs. VRd alone in patients with newly diagnosed multiple myelo...

Meeting Highlights

Gloria Espinosa, PharmD, MAT, BCOP, on Acute Lymphoblastic Leukemia: Delaying Pegaspargase Administration During Induction

Gloria Espinosa, PharmD, MAT, BCOP, of Thomas Jefferson University Hospital, discusses the delayed administration of pegaspargase for adults with acute lymphoblastic leukemia, which led to a lower rate of high-grade hepatotoxicity and su...

$Tiffany Richards, PhD, ANP-BC, AOCNP, on t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: New Findings on Venetoclax Combination$

Meeting Highlights

Tiffany Richards, PhD, ANP-BC, AOCNP, on t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: New Findings on Venetoclax Combination

Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, dives into an analysis of minimal residual disease (MRD) negativity from a phase 1/2 trial in t(11;14)-positive relapsed/refractory multiple mye...

$Amber Koehler, MPAS, PA-C, on 3-Year Follow-Up of Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma$

Meeting Highlights

Amber Koehler, MPAS, PA-C, on 3-Year Follow-Up of Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma

Amber Koehler, MPAS, PA-C, of Mayo Clinic discusses an updated analysis of the CD20xCD3 T-cell engaging bispecific antibody, mosunetuzumab, in patients with relapsed/refractory follicular lymphoma and 2 or more prior lines of therapy. Af...

Meeting Highlights

Amber Koehler, MPAS, PA-C, on Patient-Reported Quality of Life in the Largest Longitudinal Study of CLL Survivors

Amber Koehler, MPAS, PA-C, of Mayo Clinic, summarizes key points from an abstract she presented at the ASH Annual Meeting. This study, which spanned over 18 years, examined how initial management strategy (watch and wait vs. treatment) a...

Meeting Highlights

Amber Koehler, MPAS, PA-C, on Tolerability and Progression-Free Survival of Nivolumab-AVD in Advanced Stage Hodgkin Lymphoma

Amber Koehler, MPAS, PA-C, of Mayo Clinic, reports on the favorable outcomes and better tolerability of nivolumab (N) with doxorubicin, vinblastine, and dacarbazine (AVD) compared with brentuximab vedotin (BV) with AVD in patients with n...

Meeting Highlights

Racial Disparities in Cancer Mortality in Patients With GI Malignancies Following Medicaid Expansion

Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, of Cincinnati Cancer Advisors, discusses a study that aimed to investigate the effect of Medicaid expansion on racial disparities in mortality among patients with gastrointestinal malignancies....

Meeting Highlights

Adjuvant Ribociclib Plus Endocrine Therapy in Patients With HR+/HER2− Early Breast Cancer: Phase III Results

Lisa Kottschade, APRN, MSN, CNP, FAPO, of the Mayo Clinic, discusses the NATALEE study, which evaluated adjuvant ribociclib + estrogen therapy (ET) in patients with stage II or III HR+/HER2− early breast cancer (EBC) at risk for recurren...

$Phase II Results of MonumenTAL-1: Talquetamab for Relapsed/Refractory Multiple Myeloma$

Meeting Highlights

Phase II Results of MonumenTAL-1: Talquetamab for Relapsed/Refractory Multiple Myeloma

Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma. Pivotal phase II talquetamab data showed > 70% ORR in h...

Meeting Highlights

Durvalumab With Paclitaxel/Carboplatin and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab, and Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer Without a Tumor BRCA1/2 Mutation: Phase III Results

Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, of Cincinnati Cancer Advisors, discusses the phase III DUO-O trial, which evaluates paclitaxel/carboplatin (PC) followed by maintenance bevacizumab (Arm 1); PC plus bevacizumab plus durvalumab ...

Meeting Highlights

Adjuvant Osimertinib In Patients With Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Final Overall Survival Analysis

Lisa Kottschade, APRN, MSN, CNP, FAPO, of the Mayo Clinic, discusses the planned final overall survival analysis from the ADAURA trial. This study randomized eligible patients (stage IB, II, or IIIA NSCLC) to osimertinib 80 mg once daily...

Meeting Highlights

Subgroup Analysis of Elderly Patients With Diffuse Large B-Cell Lymphoma in the Phase III POLARIX Study

Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses a subgroup analysis of elderly patients enrolled in the phase III POLARIX study. In POLARIX, polatuzumab vedotin plus rituximab, cyclopho...

Meeting Highlights

HER2-Expressing Solid Tumors: Efficacy and Safety of Trastuzumab Deruxtecan

Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, of Cincinnati Cancer Advisors, discusses interim results from the DESTINY-PanTumor02 trial, the first tumor-agnostic global study of fam-trastuzumab deruxtecan-nxki (T-DXd) in a broad range of ...

Meeting Highlights

New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax

Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax (IVO) is not superio...

Meeting Highlights

High-Risk Resected Melanoma: Survival Results With mRNA-4157 and Pembrolizumab in KEYNOTE-942

Lisa Kottschade, APRN, MSN, CNP, FAPO, of the Mayo Clinic, discusses the use of the mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma, which prolonged distant metastasis–free survival...

Meeting Highlights

Lindsey M. Lyle, MS, PA-C, on MDS and Oligoblastic AML: New Data on Eprenetapopt and Azacitidine

Lindsey M. Lyle, MS, PA-C, of the University of Colorado Anschutz Medical Campus, discusses findings from a long-term follow-up of the combination of eprenetapopt and azacitidine in patients with TP53-mutant myelodysplastic syndromes (MD...

Meeting Highlights

Lindsey M. Lyle, MS, PA-C, on Advancing Personalized Care for Patients With Myeloproliferative Neoplasms

Lindsey M. Lyle, MS, PA-C, of the University of Colorado Anschutz Medical Campus, discusses results from a quality improvement initiative in which health-care professionals in two large hospital systems in the United States identified ch...

Meeting Highlights

Sandra Kurtin, PhD, ANP-C, AOCN, on a Survey of Chemotherapeutic Prescribing Practices Among Oncology Advanced Practice Providers

Sandra Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses a survey that provided insight into the wide range of advanced practice providers’ chemotherapy prescribing practices throughout the United States and...

Meeting Highlights

Sandra Kurtin, PhD, ANP-C, AOCN, on Patient-Provider Communication and the Patient Experience

Sandra Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses results from a study that showed patients with lymphoma or chronic lymphocytic leukemia who have taken part in a clinical trial generally are more con...

Meeting Highlights

Lindsey M. Lyle, MS, PA-C, on Paroxysmal Nocturnal Hemoglobinuria: New Findings on Pegcetacoplan Treatment

Lindsey M. Lyle, MS, PA-C, of the University of Colorado Anschutz Medical Campus, discusses phase III data from the PRINCE study, which showed that patients with paroxysmal nocturnal hemoglobinuria who were naive to complement-inhibitor ...

$Kathryn Tyler Maples, PharmD, BCOP, on Relapsed/Refractory Multiple Myeloma: Clinical Outcomes After Treatment With Bispecific Antibodies$

Meeting Highlights

Kathryn Tyler Maples, PharmD, BCOP, on Relapsed/Refractory Multiple Myeloma: Clinical Outcomes After Treatment With Bispecific Antibodies

Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses data of key importance for advanced practitioners on patients with multiple myeloma who are heavily pretreated and predominantly triple-class ...

$Kathryn Tyler Maples, PharmD, BCOP, on Elranatamab for Patients With Relapsed or Refractory Multiple Myeloma$

Meeting Highlights

Kathryn Tyler Maples, PharmD, BCOP, on Elranatamab for Patients With Relapsed or Refractory Multiple Myeloma

Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses findings from the MagnetisMM-1 trial on elranatamab, a humanized bispecific molecule that targets BCMA expressed in multiple myeloma and engag...

Meeting Highlights

Kathryn Tyler Maples, PharmD, BCOP, on Multiple Myeloma Treatment With Teclistamab: Early Results on Safety and Efficacy

Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses phase I/II findings from the MajesTEC-1 trial, which seems to confirm that teclistamab monotherapy induces deep and durable responses in heavi...

Meeting Highlights

Sandra Kurtin, PhD, ANP-C, AOCN, on Aggressive B-Cell Lymphoma After Failure of Anti-CD19 CAR T-Cell Therapy: Outcomes and Treatment Patterns

Sandra Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the largest reported analysis to date of patients with aggressive B-cell lymphoma who developed progressive disease after CAR T-cell therapy. This is ...

Meeting Highlights

Erin Grannan, PharmD, BCOP, on Treating Early-Stage Triple-Negative Breast Cancer With Pembrolizumab and Chemotherapy

Erin Grannan, PharmD, BCOP, of The University of Texas MD Anderson Cancer Center, discusses the KEYNOTE-522 trial and new phase III findings of interest to advanced practitioners. In the study, researchers found a generally consistent ev...

Meeting Highlights

Sheeba Cantanelli, MPAS, PA-C, on Pembrolizumab Plus Chemotherapy for Previously Untreated, Locally Recurrent, Inoperable or Metastatic Triple-Negative Breast Cancer

Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Simmons Cancer Center, discusses the final phase III results of KEYNOTE-355, which advanced practitioners need to be aware of. The study showed that pembrolizumab and chemotherapy improve...

Meeting Highlights

Donna Kinzler, DNP, ACNP-BC, AOCNP, on HR+/HER2– Early Breast Cancer and Palbociclib Treatment

Donna Kinzler, DNP, ACNP-BC, AOCNP, of the Allegheny Health Network Cancer Institute, discusses phase III findings from the PALLAS study of interest to advanced practitioners. The trial showed that adding 2 years of palbociclib to ongoin...

Meeting Highlights

Donna Kinzler, DNP, ACNP-BC, AOCNP, on Metastatic Breast Cancer: Margetuximab, Chemotherapy, and Trastuzumab

Donna Kinzler, DNP, ACNP-BC, AOCNP, of the Allegheny Health Network Cancer Institute, discusses the SOPHIA study, which APs need to be aware for their practice. The phase III trial compared margetuximab-cmkb plus chemotherapy (CTX) vs tr...

Meeting Highlights

Sheeba Cantanelli, MPAS, PA-C, on HR-Positive Advanced Breast Cancer: New Findings on Entinostat and Exemestane

Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Simmons Cancer Center, discusses phase III results of a study which showed that when entinostat, an orally bioavailable HDAC inhibitor, is combined with exemestane, it can improve progres...

Meeting Highlights

Erin Grannan, PharmD, BCOP, on HER2-Positive Metastatic Breast Cancer, Trastuzumab Deruxtecan, and Trastuzumab Emtansine

Erin Grannan, PharmD, BCOP, of The University of Texas MD Anderson Cancer Center, discusses the phase III DESTINY-Breast03 trial, which compared ado-trastuzumab deruxtecan (T-DXd) with standard-of-care trastuzumab emtansine (T-DM1) in pa...

Meeting Highlights

Sheeba Cantanelli, MPAS, PA-C, on Metformin and Adjuvant Breast Cancer Outcomes

Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Simmons Cancer Center, discusses phase III findings that showed metformin, which has been linked to beneficial anticancer effects in some research, did not improve invasive disease–free s...

Meeting Highlights

Donna Kinzler, DNP, ACNP-BC, AOCNP, on Mechanisms of Resistance to Anti-HER2 Therapy for Metastatic Breast Cancer

Donna Kinzler, DNP, ACNP-BC, AOCNP, of the Allegheny Health Network Cancer Institute, discusses a genomic analysis of 733 HER2-positive breast cancers, which identified recurrent pathway alterations associated with anti-HER2 resistance a...

Meeting Highlights

Erin Grannan, PharmD, BCOP, on Triple-Negative and Metastatic Breast Cancers: New Treatment Results on Neratinib, Fulvestrant, and Trastuzumab

Erin Grannan, PharmD, BCOP, of The University of Texas MD Anderson Cancer Center, discusses the latest updates from the SUMMIT trial that advanced practitioners need to be aware of. Researchers explored the promising combinations of nera...

Meeting Highlights

Alexis C. Geppner, MLS, CTTS, PA-C, on ALL and Hyper C-VAD: Lessons Learned and New Approaches

Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses key data that advanced practitioners need to know about treatment for patients with acute lymphocytic leukemia, the shift away from inten...

Meeting Highlights

Alexis C. Geppner, MLS, CTTS, PA-C, on IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy

Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses important updates that advanced practitioners need to be aware of when treating patients with acute myeloid leukemia, including two key d...

Meeting Highlights

Alexis C. Geppner, MLS, CTTS, PA-C, on Targeting p53 in MDS

Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses key information for advanced practitioners on the impact of TP53 mutations on prognosis in myelodysplastic syndrome, the implications of ...

Meeting Highlights

Lisa Nodzon, PhD, ARNP, AOCNP, on Myelofibrosis: New Therapeutic Approaches

Lisa Nodzon, PhD, ARNP, AOCNP, of the H. Lee Moffitt Cancer Center & Research Institute, discusses potential new treatment strategies for patients with myelofibrosis that advanced practitioners should be aware of, including anemia th...

Meeting Highlights

Lisa Nodzon, PhD, ARNP, AOCNP, on Richter Syndrome: Therapeutic Strategies

Lisa Nodzon, PhD, ARNP, AOCNP, of the H. Lee Moffitt Cancer Center & Research Institute, discusses an update on treating Richter Syndrome, including information on clonally related vs unrelated variants of the disease; the role of ve...

Meeting Highlights

Lisa Nodzon, PhD, ARNP, AOCNP, on BCMA-Directed CAR-T Cells: Early Results and Future Directions

Lisa Nodzon, PhD, ARNP, AOCNP, of the H. Lee Moffitt Cancer Center & Research Institute, discusses key information for advanced practitioners on the B-cell maturation antigen, a target for multiple myeloma, and CAR T-cell therapy, no...

Meeting Highlights

Kelly Valla, PharmD, BCOP, on T-Cell Lymphoma: Immunotherapy Approaches

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses updates on CAR T-cell therapy and what advanced practitioners need to be aware of when treating patients with rare lymphomas: how best to sequence thes...

Meeting Highlights

Kelly Valla, PharmD, BCOP, on Aggressive B-Cell Lymphoma: The Next Wave of Novel Agents

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses important data that advanced practitioners need to know about bispecific antibodies in the pipeline such as mosunetuzumab, glofitamab, and epcoritamab ...

$Kelly Valla, PharmD, BCOP, on Relapsed/Refractory MCL: Novel Treatment Approaches$

Meeting Highlights

Kelly Valla, PharmD, BCOP, on Relapsed/Refractory MCL: Novel Treatment Approaches

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses mantle cell lymphoma and what advanced practitioners should know about improving outcomes in relapsed and refractory disease with BTK inhibitors such a...

Meeting Highlights

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, on Daratumumab, Pomalidomide, and Dexamethasone for Multiple Myeloma Treatment

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses what advanced practitioners need to know about phase III findings on subcutaneous daratumumab plus pomalidomide and dexamethasone. C...

Meeting Highlights

Sandra Kurtin, PhD, ANP-C, AOCN, on COVID-19 in Patients With Hematologic Malignancies: High False-Negative Rate With High Mortality

Sandra Kurtin, PhD, ANP-C, AOCN, of The University of Arizona Cancer Center, discusses the challenges for advanced practitioners treating patients with hematologic malignancies who are at high risk for COVID-19 infection. However, the ...

Meeting Highlights

Sara Tinsley, PhD, APRN, AOCN, on CLL: Minimal Residual Disease After Venetoclax and Rituximab Therapy

Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses what advanced practitioners need to know about the findings of the MURANO study, which analyzed patients with relapsed or refractory chronic lymphocytic leukemia who had ...

Meeting Highlights

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, on Multiple Myeloma: Patient-Reported Experiences With Belantamab Mafodotin

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses key insights for advanced practitioners from the DREAMM-2 study, which detailed the self-reported experiences of patients with relap...

Meeting Highlights

Sandra Kurtin, PhD, ANP-C, AOCN, on The Burkitt Lymphoma International Prognostic Index

Sandra Kurtin, PhD, ANP-C, AOCN, of The University of Arizona Cancer Center, discusses what advanced practitioners need to know about a novel prognostic index specific to Burkitt lymphoma. The index can identify patients for whom treatme...

$Sara Tinsley, PhD, APRN, AOCN, on B-Cell Lymphoma: Phase Ib/II Data on ViPOR for Relapsed or Refractory Disease$

Meeting Highlights

Sara Tinsley, PhD, APRN, AOCN, on B-Cell Lymphoma: Phase Ib/II Data on ViPOR for Relapsed or Refractory Disease

Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses early insights for advanced practitioners on the safety, efficacy, and toxicities of the drug regimen known as ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and...

Meeting Highlights

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, on Converting Minimal Residual Disease in Multiple Myeloma

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses what advanced practitioners need to understand about maintenance treatments with carfilzomib and lenalidomide, and conversion from m...

Meeting Highlights

Sandra Kurtin, PhD, ANP-C, AOCN, on Long-Term Side Effects Among Patients With Primary Cold Agglutinin Disease

Sandra Kurtin, PhD, ANP-C, AOCN, of The University of Arizona Cancer Center, discusses the role advanced practitioners can play in managing the unmet medical needs of patients with primary cold agglutinin disease, many of whom had severe...

Meeting Highlights

Sara Tinsley, PhD, APRN, AOCN, on MDS: Pevonedistat and Azacitidine for Higher-Risk Disease

Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses what advanced practitioners need to understand about the findings on safety and efficacy of pevonedistat plus azacitidine vs azacitidine alone in patients with higher-r...

Meeting Highlights

Allyson Price, MPAS, PA-C, on Predicting Drug Response in Acute Lymphoblastic Leukemia

Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses gene drug mapping, the future of precision medicine in leukemia, and the need for advanced practitioners to educate this patient population who ma...

Meeting Highlights

Allyson Price, MPAS, PA-C, on Immunotherapy for T-Cell ALL and T-NHL

Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses the Keynote lecture on two complex disease states, the vital role advanced practitioners play in managing patients on CAR-T therapies, and explain...

Meeting Highlights

Allyson Price, MPAS, PA-C, on Oral HMAs for Myelodysplastic Syndrome

Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses oral hypomethylating agents for MDS, and the implications for advanced practitioners helping patients adhere to the new regimens and maintain good...

Meeting Highlights

Lisa Nodzon, PhD, ARNP, AOCNP, on Myelofibrosis: New Therapies in Development

Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses agents in phase III studies (both ongoing and planned), how the treatment landscape for myelofibrosis is changing, and what advanced practitioners need to know about mana...

Meeting Highlights

Lisa Nodzon, PhD, ARNP, AOCNP, on Multiple Myeloma: Managing Early Relapse

Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses new drug combinations to treat multiple myeloma, the challenges of managing relapsed and refractory disease, and the role that advanced practitioners need to play in educ...

Meeting Highlights

Lisa Nodzon, PhD, ARNP, AOCNP, on CLL: Measuring Residual Disease

Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses the progress made in treating chronic lymphocytic leukemia, the clinical implications of undetectable minimal residual disease in blood and bone marrow, and how advanced ...

$Kelly Valla, PharmD, BCOP, on Relapsed or Refractory Hodgkin Lymphoma: Integrating Novel Agents$

Meeting Highlights

Kelly Valla, PharmD, BCOP, on Relapsed or Refractory Hodgkin Lymphoma: Integrating Novel Agents

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses what advanced practitioners need to know about integrating brentuximab vedotin and PD-1 blockade earlier in the care of patients with Hodgkin lymphoma,...

Meeting Highlights

Kelly Valla, PharmD, BCOP, on Peripheral T-Cell Lymphoma: Managing Relapsed Disease

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses insights for advanced practitioners on the many facets of treating peripheral T-cell lymphoma, including stem cell transplants, single agents vs combin...

Meeting Highlights

Kelly Valla, PharmD, BCOP, on Cellular Therapy: New CAR Designs

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses next-generation CAR T cells and what advanced practitioners need to understand about enhanced cytotoxicity and increased persistence of the cells, endo...

Meeting Highlights

Sandra E. Kurtin, PhD, ANP-C, AOCN, on Multiple Myeloma in Older Patients: Isatuximab With Pomalidomide and Dexamethasone

Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses data from the ICARIA-MM trial that show adding isatuximab to pomalidomide and dexamethasone improved progression-free survival, overall survival, o...

Meeting Highlights

Amy Pierre, ANP-BC, on CLL in Older Patients: The Alliance Trial on Ibrutinib, Obinutuzumab, and Venetoclax

Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses a currently enrolling phase III trial on a new strategy to decrease exposure time to ibrutinib, which has the potential to change the standard of care for patients ...

Meeting Highlights

Amy Pierre, ANP-BC, on Multiple Myeloma: Autologous Stem Cell Transplant in Older Patients

Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses study findings on the decreased use of autologous stem cell transplant in older patients with multiple myeloma, despite the therapy’s significant survival benefit. ...

Meeting Highlights

Sara Tinsley, PhD, APRN, AOCN, on MDS: MEDALIST Trial of Luspatercept to Treat Anemia

Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses study findings that showed most patients with lower-risk myelodysplastic syndrome treated with luspatercept, a first-in-class erythroid maturation agent, achieved indepen...

Meeting Highlights

Sandra E. Kurtin, PhD, ANP-C, AOCN, on Treating CLL in the Community Setting: Early Discontinuation of First-Line Ibrutinib

Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the findings of a retrospective study that assessed the use of first-line ibrutinib for chronic lymphocytic leukemia in the United States. Although...